1 hr ago
Sun Pharma Secures Global Rights to Monthly Cholesterol Drug
Sun Pharma has made a deal to sell and make a cholesterol medicine called lerodalcibep in many parts of the world.
The deal does not include the United States or China.
The medicine is given as one injection each month.
It helps lower LDL cholesterol, often called bad cholesterol.
In the European Union, it is sold as Lyrokaul.
In the United States, it is sold as Lerochol, but Sun Pharma does not have rights there under this deal.
LIB will receive an upfront payment, future milestone payments and royalties from sales.
Sun Pharma says the deal will strengthen its medicines business, especially in heart and blood-vessel care.
Sun Pharma will exclusively commercialise and manufacture lerodalcibep worldwide, excluding the United States and China.
The agreement with LIB includes upfront and milestone payments plus royalties tied to net sales; other financial terms were not disclosed.
Lerodalcibep is a once-monthly 300 mg injection designed to reduce LDL cholesterol.
The drug is approved in the European Union as Lyrokaul and in the United States as Lerochol.
The PCSK9 inhibitor market outside the United States and China reached $3.7 billion in the 12 months ended Q2 2026, according to IQVIA.
- Who
- Sun Pharma and LIB are parties to the licensing agreement; Sun Pharma Managing Director Kirti W Ganorkar commented on the deal.
- What
- Sun Pharma received exclusive rights to commercialise and manufacture lerodalcibep in licensed territories worldwide, excluding the United States and China.
- Where
- The rights cover licensed territories worldwide except the United States and China, including the European Union.
- When
- The market data covers the 12 months ended Q2 2026; the announcement’s specific signing date was not stated.
- Why
- The agreement expands Sun Pharma’s Innovative Medicines portfolio and gives it access to a growing PCSK9 inhibitor market.
Key facts
- Medicine
- Lerodalcibep, a once-monthly PCSK9 inhibitor
- Dosage
- 300 mg subcutaneous injection once a month
- European Union brand
- Lyrokaul
- United States brand
- Lerochol
- Territory
- Worldwide excluding the United States and China
- Market size
- US$3.7 billion outside the United States and China in the 12 months ended Q2 2026
- European market
- US$2.9 billion during the same period
Quotes
Kirti W Ganorkar
Managing Director of Sun Pharma
“Once-monthly lerodalcibep dosing, with robust LDL-C reduction and the added benefits of a small-volume injection and six-month ambient storage, simplifies treatment for patients and offers greater convenience.”
businesstoday.in
Sources
Related news
Cipla Signs Exclusive Pact for Experimental Breast Cancer Drug
India’s Lipid Burden Raises Questions About Medicalization and Treatment
Kwality Pharmaceuticals Builds Growth Through Global Registrations and Pipelines
Sun Pharma Wins Investment-Grade Ratings for Organon Bid
Sun Pharma Trades Lower Drug Prices for US Tariff Relief
Cipla, Qilu Partner on Keytruda Biosimilar for US Patients
Gates Warns AI Could Cause Billion Deaths Amid Regulation Debate
US and China Release Lists for Planned Tariff Cuts
UN Leaders Urge Youth Investment, Warn AI May Widen Inequality
US-China Board Proposes Tariff Cuts Covering $30 Billion Each Way
Taiwan urges deeper drone cooperation with democratic partners amid tensions
